



Hosts the

# **11<sup>th</sup> International Symposium on Translational Research in Oncology**

Chairs: Prof John Crown (Dublin)  
Prof Robert Kerbel (Toronto)  
Prof Mario Sznol (Yale)

**Thursday, Friday & Saturday  
September 27<sup>th</sup>, 28<sup>th</sup> & 29<sup>th</sup> 2018**

*Herbert Park Hotel, Ballsbridge, Dublin 4*

## **40 Speakers include:**

Dr Richard Finn (UCLA), Dr. Sara Hurvitz (UCLA),  
Dr. Mark Pegram (Stanford), Dr. Cliona Rooney (Texas),  
Dr Steve Shak (Genomic Health), Dr. Maeve Lowery (TCD),  
Dr. Lillian Smyth (MSKCC) , Dr Maurizio Scaltriti (MSKCC),  
Prof Lajos Pusztai (Yale), Dr Kevin Curran (MSKCC),

**Attendance is free but registration is required.**

**Register:** [karen.culhane@ccrt.ie](mailto:karen.culhane@ccrt.ie)

**Website:** <http://www.ccrt.ie>

**External CPD credits: 4 (27<sup>th</sup>) 6 (28<sup>th</sup>) 2 (29<sup>th</sup>)**

*CHY12210*

# 11<sup>TH</sup> INTERNATIONAL SYMPOSIUM ON TRANSLATIONAL RESEARCH IN ONCOLOGY

#TransOncXI



Thursday, 27<sup>th</sup> September, Lansdowne Suite, Herbert Park Hotel, Ballsbridge, D4

Registration from 08:30

4 External CPD points

9:00 – 9:15 Welcome and Introduction – Prof John Crown, St. Vincent’s University Hospital, Dublin

## TARGETED THERAPIES

Chair: Prof John Crown

- 9:15 – 9:45 **Overcoming resistance to HER2 targeted therapy**  
*Dr. Mark Pegram, Department of Medicine, Stanford University*
- 9:45 – 10:15 **Dasatinib and HER2-targeted therapy resistance in breast cancer.**  
*Dr. Denis Collins, National Institute for Cellular Biotechnology, Dublin City University*
- 10:15–10:45 **Genomic determinants of response to therapy in breast cancer**  
*Dr. Maurizio Scaltriti, Memorial Sloan Kettering Cancer Center, New York*
- 10:45 – 11:00 *Coffee break*
- 11:00 – 11:30 **Targeting IGF Signaling in HR+ breast cancer with Xentuzumab: an update**  
*Dr. Thomas Bogenrieder, University Hospital Grosshadern, Munich & Boehringer-Ingelheim*
- 11:30– 12:00 **PRS-343 (4-1BB / HER2) is a first-in-class T-cell agonist which drives tumor localized activation of the immune system**  
*Dr Shane Olwill, VP, Head of Development & Immuno-Oncology, Pieris Pharmaceuticals*
- 12:00–12:30 **CDK 4/6 Inhibition in cancer medicine: the next phase**  
*Dr. Richard Finn, Professor of Clinical Medicine, Geffen School of Medicine, UCLA*
- 12:30- 1:00 **Targeting tumour re-wiring in ER+ endocrine resistant breast cancer**  
*Dr. Lesley-Ann Martin, Institute of Cancer Research, London*
- 1.00-2.00 *Lunch, Herbert Suite*
- 2:00-2:30 **Ladiratumumab Vedotin: A clinically active molecule with multiple potential mechanisms of action**  
*Dr. Norman Barlow, Head of Nonclinical Sciences, Seattle Genetics*
- 2:30-3.00 **Targeted therapies for BRCA mutated and triple negative breast cancers**  
*Dr. Sara Hurvitz, Division of Hematology-Oncology, Geffen School of Medicine, UCLA*
- 3:00-3:30 **AKT inhibition in AKT mutant tumors**  
*Dr. Lillian Smyth, Memorial Sloan Kettering Cancer Centre, New York*
- 3.30-3.45 *Coffee break*

## TARGETING FAMILIAL CANCERS

Chair: Dr. Dimitrios Tryfonopoulos

- 3:45-4.15 **Exploring the function of genetic variants in the non-coding genomic regions in familial breast cancer**  
*Dr. Adrian Bracken, Smurfit Institute of Genetics, Trinity College Dublin*
- 4:15-4:45 **GWAS-pathway analysis and functional validation of candidate susceptibility genes in pancreatic cancer**  
*Dr. Naomi Walsh, National Institute for Cellular Biotechnology, Dublin City University*
- 4:45-5:15 **Germline mutations in pancreatic cancer – targeting defective DNA repair**  
*Dr. Maeve Lowery, Professor of Translational Cancer Medicine, Trinity College Dublin*

*The organisation of this meeting has been funded by third party sponsors, however, none of these sponsors have had any influence over the educational/scientific content of presentations or the agenda of the meeting.*

# 11<sup>TH</sup> INTERNATIONAL SYMPOSIUM ON TRANSLATIONAL RESEARCH IN ONCOLOGY

#TransOncXI



**Friday, 28<sup>th</sup> September, Lansdowne Suite, Herbert Park Hotel, Ballsbridge, D4**

**Registration from 08:30**

**6 External CPD points**

9:00 – 9:15 Welcome and Introduction – Prof John Crown, St. Vincent’s University Hospital, Dublin

## **IMMUNOTHERAPY**

**Chair: Dr. Mario Sznol**

- 9:15 – 9:45 **Determinants of response to immune therapies**  
*Dr. Mario Sznol, Professor of Medicine, Yale Cancer Centre*
- 9:45 – 10:15 **Immunological differences between primary and metastatic breast cancer**  
*Prof. Lajos Pusztai, Director, Yale Cancer Center Genetics, Genomics and Epigenetics Program*
- 10:15 – 10:45 **TILs in breast cancer: ready for use?**  
*Prof. Giuseppe Gullo, Consultant Medical Oncologist, St. Vincent’s University Hospital, Dublin, Ireland*
- 10:45 – 11:00 *Coffee break*
- 11:00-11:30 **Immune contexture in colon cancer**  
*Prof Jérôme Galon, Laboratory of Integrative Cancer Immunology, INSERM, Paris, France*
- 11:30-12:00 **Immunotherapy in lung cancer**  
*Prof Ken O’Byrne, Princess Alexandra Hospital, Queensland University of Technology*
- 12:00-12:30 **Chimeric Antigen Receptor (CAR) T-cells for cancer immunotherapy**  
*Dr. Kevin Curran, Memorial Sloan Kettering Cancer Centre*
- 12:30 -1:00 **Improving the expansion and persistence of CAR T-cells for solid tumors**  
*Dr. Cliona Rooney, Baylor College of Medicine, Houston, Texas*
- 1:00- 2:00 Lunch, Herbert Suite*

## **ANGIOGENESIS**

**Chair: Prof Bob Kerbel**

- 2:00-2:30 **New clinical data supporting the inevitable use of anti-hypoxia-adenosinergic drugs to improve current immunotherapies of cancer.**  
*Prof Michail Sitkovsky, Northeastern University, Boston*
- 2:30-3:00 **Preclinical and clinical update on metronomic chemotherapy: where do we (I) go from here?**  
*Prof Robert Kerbel, Sunnybrook Health Science Centre, Toronto*
- 3:00-3:30 **Targeting angiogenesis and metabolism in the tumour microenvironment to boost treatment response in GI cancers**  
*Prof Jacintha O’Sullivan, Professor in Translational Oncology, Trinity Translational Medicine Institute*
- 3:30-3:45 Coffee break, Herbert Suite*
- 3:45-4:15 **Vessel co-option in cancer: mechanisms and clinical implications**  
*Dr Andrew Reynolds, Principal Medical Scientist, AstraZeneca, UK*
- 4:15-4:45 **The metastatic switch in the tumor microenvironment following anti cancer therapy**  
*Dr. Yuval Shaked, Nanotechnology Institute Technion-Israel Institute of Technology*
- 4:45-5:15 **Improving immunotherapy using novel Agent X**  
*Dr. Kairbaan Hodivala-Dilke, Barts Cancer Institute, Queen Mary University of London*

*The organisation of this meeting has been funded by third party sponsors, however, none of these sponsors have had any influence over the educational/scientific content of presentations or the agenda of the meeting.*

# 11<sup>TH</sup> INTERNATIONAL SYMPOSIUM ON TRANSLATIONAL RESEARCH IN ONCOLOGY

#TransOncXI



**Saturday 29<sup>th</sup> September, Lansdowne Suite, Herbert Park Hotel, Ballsbridge, D4**

**Registration from 8:30**

**2 External CPD points**

## **PERSONALISED MEDICINE**

**Chair: Prof. Wolfgang Eiermann**

- 9:00-9:30 **TAILORx Results – Defining Chemotherapy Benefit in Early Stage Luminal Breast Cancer**  
*Dr. Steve Shak, Chief Scientific Officer, Genomic Health*
- 9:30-10:00 **Fast-Tracking Molecular Diagnostics in Oncology**  
*Prof. William Gallagher, School of Biomolecular and Biomedical Science, University College Dublin*
- 10:00-10:30 **Genomics-Driven Oncology Drug Development**  
*Dr. Richard Williams, Managing Director and Head of Oncology Programs, WuXi NextCODE, (GMI Technology Partner)*
- 10:30-11:00 **UCLA-TORL, A Pipeline for Drug Discovery**  
*Dr. Neil O'Brien, Assistant Professor, Department of Medicine, UCLA*
- 11:00-11:15 Coffee break, Herbert Suite*

## **DNA DAMAGE REPAIR**

**Chair: Prof Joe Duffy**

- 11:15-11:45 **Developing Inhibitors Against Rare Oncogenic Kinases**  
*Michael Craig Cox, Sr Director, Clinical Development & Medical Affairs, Loxo Oncology, Inc.*
- 11:45-12:15 **Mutant p53 as a Therapeutic Target for Cancer Treatment**  
*Prof. Joe Duffy, St. Vincent's University Hospital, Clinical Research Centre, Dublin*
- 12:15-12:45 **COTI-2: preclinical and early clinical results from an orally available small molecule targeting mutant p53**  
*Dr. Richard Ho, Chief Scientific Officer, Cotinga Pharmaceuticals*
- 12:45-1:15 **Development of olaparib in prostate cancer: strategies to target homologous recombination repair deficiency**  
*Dr. Carrie Adelman, Associate Principal Translational Scientist, AstraZeneca, UK*
- 1:15-2:00 Lunch, Herbert Suite*

**Chair: Prof John Crown**

- 2:00-2:30 **Targeting Non-Homologous End Joining by M3814, a potent and selective inhibitor of DNA dependent protein kinase**  
*Dr. Frank Zenke, Head of Cellular Pharmacology, Translational Innovation Platform Oncology, Merck*
- 2:30-3:00 **CDK8/19: Targeting Metastasis and Drug Resistance**  
*Prof. Igor Roninson, Director, Centre for Targeted Therapies, University of South Carolina*
- 3:00-3:30 **Found in Translation: How Preclinical Studies are Guiding Clinical Development of the BCL-2 Inhibitor Venetoclax**  
*Dr. Joel Levenson, Scientific Director, Oncology Development, AbbVie*
- 3:30-3:45 Coffee break, Herbert Suite*

## **TARGETED THERAPIES**

**Chair: Prof Robert Leonard**

- 3:45-4:15 **Non-cytotoxic, non-antimitotic effects of eribulin on the tumor immune micro-environment**  
*Dr. Bruce Littlefield, Scientist and Head, Translational Medicine, Eisai Inc.*
- 4:15-4:45 **Sarcoma in the 21st Century: Translating New Targets into Cancer Medicine**  
*Dr. Gary Schwartz, Colombia Presbyterian University*
- 4:45-5:15 **hSSB1, a novel target for therapy in solid tumours**  
*Prof Ken O'Byrne, Princess Alexandra Hospital, Queensland University of Technology*

*The organisation of this meeting has been funded by third party sponsors, however, none of these sponsors have had any influence over the educational/scientific content of presentations or the agenda of the meeting.*